Summary:
In this video interview, recorded in March 2025, Ottimo Pharma's CEO David Epstein describes the therapeutic value of developing a PD1-VEGFR antibody, what drew him to the biotech, and what his advice would be for R&D leaders on assessing value for first-in-class therapeutics. He also highlights lessons from his past roles at Seagen, Novartis and Flagship.
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.